Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials

• Published in: Cancer treatment reviews 2022-05, Vol.106, p.102385-102385, Article 102385
• Main Authors: Monk, Bradley J., Enomoto, Takayuki, Kast, W. Martin, McCormack, Mary, Tan, David S.P., Wu, Xiaohua, González-Martín, Antonio
• Format: Article
• Language: English
• Subjects: Cervical cancer; Female; Humans; Immunologic Factors - therapeutic use; Immunotherapy; Immunotherapy - methods; Locally advanced; Metastatic; Neoplasm Recurrence, Local - drug therapy; United States; Uterine Cervical Neoplasms - drug therapy
• ISSN: 0305-7372; 1532-1967
• DOI: 10.1016/j.ctrv.2022.102385

•Two immunotherapies for recurrent/metastatic cervical cancer were approved in 2021.•Several trials are anticipated in recurrent/metastatic and locally advanced disease.•Some cases of difficult-to-treat adenocarcinoma or PD-L1-negative tumors responded.•Immunotherapy will become a new standard in the treatment of cervical cancer. Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer that commonly expresses programmed cell death ligand-1. Before 2021, pembrolizumab was the only United States Food and Drug Administration-approved immunotherapy in cervical cancer, specifically for the second-line recurrent or metastatic (r/m) setting. In late 2021, the antibody-drug conjugate tisotumab vedotin was approved for second-line r/m cervical cancer and pembrolizumab combined with chemotherapy ± bevacizumab was approved for first-line r/m disease based on results from KEYNOTE-826. Moreover, with at least 2 dozen additional immunotherapy clinical trials in the second-line and first-line r/m setting, as well as in locally advanced disease, the treatment landscape for cervical cancer may eventually encounter a potential paradigm shift. Pivotal trials of immunotherapies for cervical cancer that were recently approved or with the potential for regulatory consideration through 2024 are reviewed. As immunotherapy has the opportunity to establish new standards of care in the treatment of cervical cancers, new biomarkers to identify the ideal patient populations for these therapies may also become important. However, issues with access, affordability, and compliance in low- and middle-income countries are anticipated.